2018-19 Section 7-Neoplastic and Inflammatory Diseases of the Head and Neck eBook

Original Investigation Research

Survival Outcomes With Adjuvant Chemotherapy in Resected Major Salivary Gland Carcinoma

Table 1. Patient and Treatment Characteristics

No. (%) of Patients a RT Alone (n = 1842)

CRT (n = 368)

P Value b

Characteristic

Age, y <65

1000 (54.3) 842 (45.7)

228 (62.0) 140 (38.0)

.007

≥65

Sex

Male

1108 (60.2) 734 (39.8)

264 (71.7) 104 (28.3)

<.001

Female

Race

White

1564 (84.9)

307 (83.4) 39 (10.6)

African American

179 (9.7) 99 (5.4)

.77

Other

22 (6.0)

Insurance status Private

837 (45.4)

202 (54.9)

Medicaid Medicare

83 (4.5)

15 (4.1)

783 (42.5)

127 (34.5)

.045

Other government

26 (1.4) 47 (2.6) 66 (3.6)

5 (1.4) 7 (1.9) 12 (3.3)

Uninsured

Not specified

Median annual income quartile, $ <30 000

77 (4.2)

12 (3.3) 47 (12.8) 55 (14.9) 94 (25.5) 160 (43.5)

30 000-34 999 35 000-45 999

242 (13.1) 327 (17.8) 488 (26.5) 708 (38.4)

.38

≥46 000 Unknown

Residence

Metropolitan

1510 (82.0) 291 (15.8)

310 (84.2) 51 (13.9)

Urban Rural

.58

41 (2.2)

7 (1.9)

Charlson-Deyo comorbidity score c 0

1095 (59.4) 152 (8.3) 31 (1.7) 564 (30.6)

269 (73.1) 45 (12.2) 14 (3.8) 40 (10.9)

1

<.001

≥2

Unknown

Facility type Community cancer program

172 (9.3) 918 (49.8) 751 (40.8)

27 (7.3)

Comprehensive community program Academic or research (includes NCI)

142 (38.6) 199 (54.1)

<.001

Other

1 (0.1)

0

Year of diagnosis 1998-2004

751 (40.8) 1091 (59.2)

155 (42.1) 213 (57.9)

.63

2005-2011

Primary tumor site Parotid gland

1555 (84.4) 227 (12.3)

297 (80.7) 49 (13.3)

Submandibular gland

.005

Sublingual gland Major gland NOS

15 (0.8) 45 (2.4)

1 (0.3) 21 (5.7)

(continued)

90) years; for those undergoing CRT, 62 (range, 18-88) years. Sites ofmost of the included caseswere the parotid gland (1852 [83.8%]), followed by the submandibular gland (276 [12.5%]), any major gland not otherwise specified (66 [3.0%]), and the

in the study; of these, 1842 (83.3%) received RT alone and 368 (16.7%) received CRT ( Figure 1 and Table 1 ). The median fol- low-up for the entire cohort was 39 (range, 2-188)months. The median age of patients undergoing RT alonewas 64 (range, 18-

(Reprinted) JAMA Otolaryngology–Head & Neck Surgery November 2016 Volume 142, Number 11

jamaotolaryngology.com

Copyright 2016 American Medical Association. All rights reserved.

37